Baseline kidney function appeared to modify the effects of the SGLT2 inhibitor canagliflozin compared to placebo on stroke in the CANVAS Program. We extracted data from the EMPA-REG OUTCOME, DECLARE-TIMI… Click to show full abstract
Baseline kidney function appeared to modify the effects of the SGLT2 inhibitor canagliflozin compared to placebo on stroke in the CANVAS Program. We extracted data from the EMPA-REG OUTCOME, DECLARE-TIMI 58 and CREDENCE trials to define more completely the effects of SGLT2 inhibition on stroke
               
Click one of the above tabs to view related content.